Fluorescence-guided surgery (FGS) represents a significant advancement in the precise resection of tumors and pathological tissues. However, the complexity of the procedures, especially in neuro-oncology, hepatobiliary, and orthopedic oncology, necessitates a nuanced approach to postoperative rehabilitation. This review explores evidence-based rehabilitation strategies tailored to function-specific recovery pathways following FGS. It highlights the current understanding of epidemiology, pathophysiology, risk factors, clinical features, and diagnostic considerations that inform individualized post-surgical rehabilitation. The discussion integrates recent advances, emerging therapies, and guideline recommendations, emphasizing the need for multidisciplinary collaboration to optimize functional outcomes, minimize complication rates, and maximize patient quality of life.
Fluorescence-guided surgery leverages intraoperative imaging using fluorescent dyes such as 5-aminolevulinic acid (5-ALA), indocyanine green (ICG), or other tumor-specific tracers to enhance intraoperative visualization of malignant tissue. This approach increases the completeness of tumor resection while sparing healthy tissue, but may introduce unique postoperative challenges. The transition from intraoperative precision to postoperative recovery demands a paradigm shift in rehabilitation, where function-specific pathways are essential for restoring neurological, musculoskeletal, or organ-specific function. The integration of rehabilitation medicine into the surgical continuum is critical for optimizing patient-centered outcomes and aligns with modern principles of multidisciplinary cancer and surgical care.
FGS is increasingly utilized in the management of high-grade gliomas, liver metastases, and musculoskeletal sarcomas. Epidemiological studies report that more than 60% of resectable glioblastomas in tertiary centers employ 5-ALA FGS, while ICG is routinely used in hepatocellular carcinoma and colorectal liver metastasis resections. Despite improvements in surgical margins, the perioperative morbidity and long-term functional deficits remain significant, with up to 40% of patients requiring intensive inpatient rehabilitation postoperatively. The burden of persistent neurological, motor, or visceral dysfunction underscores the need for structured, evidence-driven rehabilitation programs tailored to the type and location of surgical intervention.
The pathophysiological basis for functional impairment after FGS varies by anatomical site. In neuro-oncology, manipulation and resection near eloquent cortex or subcortical tracts can result in focal neurological deficits, such as hemiparesis, aphasia, or visual field cuts, due to direct tissue disruption, peri-lesional edema, or ischemic injury. Hepatobiliary FGS may lead to compromised hepatic reserve or biliary dysfunction, while musculoskeletal FGS can cause soft tissue and nerve injuries. Fluorescent agents themselves rarely cause direct tissue toxicity, but their use facilitates more aggressive resections, potentially increasing risk for functional compromise. The delicate interplay between surgical precision and the biological response to injury is central to planning individualized rehabilitation protocols.
Risk factors for adverse functional outcomes after FGS include tumor proximity to critical structures, pre-existing neurological or organ dysfunction, extent of resection, patient age, comorbidities, intraoperative complications, and perioperative inflammatory response. Studies suggest that patients with preoperative functional impairment, high tumor burden, or poor baseline performance status are at greater risk for prolonged or incomplete recovery. The use of higher-dose fluorescent agents or prolonged surgical times may also contribute to transient neurological or systemic dysfunction, necessitating risk stratification in preoperative planning and postoperative rehabilitation pathway selection.
Postoperative clinical features following FGS are dependent on the anatomical region involved. In neuro-oncology, motor weakness, sensory changes, speech disturbances, and cognitive deficits are common. Hepatobiliary procedures may result in jaundice, coagulopathy, or hepatic encephalopathy, while musculoskeletal resections can cause limb weakness, gait disturbances, or chronic pain syndromes. Early identification of such features through standardized assessment scales, such as the NIH Stroke Scale, Karnofsky Performance Status, and Barthel Index, facilitates targeted intervention and monitoring of rehabilitation progress.
Accurate diagnosis of postoperative deficits requires comprehensive neurological, functional, and organ-specific assessment. Imaging modalities such as MRI, CT, and ultrasound are employed alongside electrophysiological studies and laboratory investigations to delineate the extent of injury and recovery potential. Functional assessments, including gait analysis, muscle strength grading, and neuropsychological testing, guide the formulation of individualized rehabilitation plans. Regular interdisciplinary team meetings ensure prompt recognition of complications such as infection, bleeding, or delayed neurological deterioration, enabling timely adjustments to the rehabilitation regimen.
Rehabilitation after FGS is predicated upon early mobilization, prevention of complications, and restoration of function through targeted therapy. In neuro-oncology, intensive physical, occupational, and speech therapy are initiated within 24–48 hours postoperatively, focusing on neuroplasticity and functional compensation. Hepatobiliary and musculoskeletal FGS patients benefit from tailored exercise programs, nutritional optimization, and pain management protocols. The use of assistive devices, adaptive technology, and patient education are integral to maximizing independence and participation. Close collaboration between surgeons, physiatrists, therapists, and nursing staff underpins the success of these interventions.
Emerging rehabilitation strategies incorporate robotics-assisted therapy, virtual reality platforms, and neuromodulation techniques such as transcranial magnetic stimulation (TMS) and functional electrical stimulation (FES) to enhance motor recovery and cortical reorganization. Pharmacological adjuncts, including selective serotonin reuptake inhibitors and neurotrophic factors, are under investigation for their role in promoting neuroplasticity. Machine learning algorithms and wearable technology are being deployed for real-time monitoring of functional status, enabling dynamic adjustment of rehabilitation intensity. Recent randomized controlled trials demonstrate that intensive, function-specific rehabilitation pathways yield superior outcomes compared to generic programs, particularly in the early post-FGS period.
Current guidelines from the American Academy of Physical Medicine and Rehabilitation (AAPMR), National Comprehensive Cancer Network (NCCN), and European Association of Neuro-Oncology (EANO) advocate for early, individualized, and multidisciplinary rehabilitation after FGS. Protocols emphasize prehabilitation, risk stratification, early mobilization, and regular reassessment of functional goals. Integration of patient-reported outcomes and shared decision-making is recommended to personalize rehabilitation objectives and improve adherence. Ongoing education for healthcare providers on the unique aspects of FGS recovery is crucial for the implementation of guideline-directed care.
Rehabilitation following fluorescence-guided surgery demands a comprehensive, function-specific approach grounded in recent evidence and best practice guidelines. Early and individualized intervention, supported by interdisciplinary collaboration and advanced technologies, can mitigate postoperative deficits and enhance patient quality of life. As FGS becomes more prevalent across surgical disciplines, continued research and guideline refinement are needed to optimize recovery pathways and ensure equitable access to high-quality rehabilitative care.
1.
Future of Lab-Developed Tests Still Taking Shape
2.
Tafasitamab Combo Boosts R-CHOP in Frontline DLBCL
3.
WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research
4.
After a plane crash, a surgeon dies; Austin is released from the hospital; and an animal pandemic spreads.
5.
Q&A: Breast cancer facts that could save lives
1.
Patient-Centric Approaches in Hematology: Integrating Individualized Care into Modern Clinical Practice
2.
Revolutionizing Cancer Treatment: Harnessing the Power of AI in Histopathology
3.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
4.
Clinical Pharmacology of Erythropoiesis-Stimulating Pathway Modulators
5.
Innovative Pathways in Oncology Across Clinical Settings
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
2.
Early warning sings of camcer that need medical attention
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Understanding Common Causes of Abnormal Blood Counts
5.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation